

In re Application of:

Brian Bennett

Application No.: Not Yet Assigned

US Submission Date: December 12, 2005

Based on Intl Appl: PCT/GB2004/002854

IA Filing Date: July 1, 2004

Page 5

PATENT

Attorney Docket No.: KILBURN1180

*Renumbered per rule 126*

*CC*

**B. In the Claims**

Please cancel claims 5 to 6 without prejudice. Please amend claim 1 and claims 7 to 22 as follows.

Upon entry of the present amendment, the claims will stand as follows in the present application:

1. (currently amended) A barrier formulation which comprises an emulsion having at least an oil phase comprising a silicone compound and an aqueous phase, the viscosity of the formulation being 20000 cps 20 Pascal second (20000 cps) or less, and the formulation further comprising an active ingredient selected from triclosan and alexidine present in an amount from 0.5 to 10% by weight of the formulation, and one or more of an emollient, an excipient, a thickener, an emulsifier, a neutralizing agent, a preservative, and water.

2. (original) A formulation as defined in claim 1 wherein the silicone compound is a silicone fluid.

3. (original) A formulation as defined in claim 2, wherein the silicone fluid is selected from dimethicone, a silicone emulsion, a dimethicone cross polymer, and a polydimethylsiloxane.

4. (currently amended) A formulation as defined in any one of the preceding claimsclaim 1, which comprises from 0.1 to 10% by weight, from 0.5 to 5% by weight, or from 1% to 2% by weight of the silicone compound.

In re Application of:

Brian Bennett

Application No.: Not Yet Assigned

US Submission Date: December 12, 2005

Based on Intl Appl: PCT/GB2004/002854

IA Filing Date: July 1, 2004

Page 6

PATENT

Attorney Docket No.: KILBURN1180

Claims 5-6 (canceled).

7 ~~75.~~ (currently amended) A formulation as defined in any one of the preceding claimsclaim 1, wherein the active ingredient is present in an amount from 0.5 to 10% by weight of the formulation, from 1 to 5% by weight, or about 2% by weight.

8 ~~86.~~ (currently amended) A formulation as defined in any one of the preceding claimsclaim 1 which further comprises a fragrance.

9 ~~97.~~ (currently amended) A formulation as defined in any one of the preceding claimsclaim 1, wherein the formulation comprises the following ingredients in the approximate ranges indicated:

Ingredient	Range (wt%)
Castor oil	0.5-3.0
Stearic acid	0.5-8.0
Glycerol stearate	0.1-3.0
Cetyl palmitate	0.1-2.0
Silicone fluid	0.1-10
Nipastat	0.1-0.5
Jojoba oil	0.1-0.5
Liquid paraffin	0.1-0.5
Active ingredient	0.5-10
Water	35-95
Carbomer	0.5-8.0
Aleo vera	0.1-2.0
Monopropylene glycol	2.0-15
Triethanolamine	0.1-2.0

In re Application of:

Brian Bennett

Application No.: Not Yet Assigned

US Submission Date: December 12, 2005

Based on Intl Appl: PCT/GB2004/002854

IA Filing Date: July 1, 2004

Page 7

PATENT

Attorney Docket No.: KILBURN1180

10

~~108.~~ (currently amended) A barrier formulation as defined in ~~any one of the preceding claims~~claim 1, for use as a skin barrier for humans or animals.

11

~~112.~~ (currently amended) A barrier formulation as defined in ~~any one of claims 1 to 9~~claim 1, for use in medicine, including veterinary medicine.

12

~~1210.~~ (currently amended) Use of a formulation as defined in ~~any one of claims 1 to 9~~claim 1, in the manufacture of a medicament for use in the treatment and/or prophylaxis of infections.

13

~~1311.~~ (currently amended) Use of a formulation as defined in ~~claim 12~~claim 10 wherein the medicament is for use in the treatment and/or prophylaxis of skin infections.

14

~~1412.~~ (currently amended) Use of a formulation as defined in ~~claim 12~~claim 10, wherein the medicament is for use in the treatment and/or prophylaxis of hospital acquired infections.

15

~~1513.~~ (currently amended) Use of a formulation as defined in ~~claims 12 or 13~~claim 10, wherein the medicament is for use in the treatment and/or prophylaxis of skin infections in animals.

16

~~1614.~~ (currently amended) Use of a formulation as defined in ~~claim 15~~claim 13, wherein the medicament is for use in the treatment and/or prophylaxis of mastitis infection and/or the spread of mastitis infection between farm animals.

In re Application of:

Brian Bennett

Application No.: Not Yet Assigned

US Submission Date: December 12, 2005

Based on Intl Appl: PCT/GB2004/002854

IA Filing Date: July 1, 2004

Page 8

PATENT

Attorney Docket No.: KILBURN1180

17

~~1715~~ (currently amended) Use of a formulation as defined in ~~claim 15~~claim 13, wherein the medicament is for use in the treatment and/or prophylaxis of teat sores in animals.

18

~~1816~~ (currently amended) A method for the treatment and/or prophylaxis of skin conditions, the method comprising applying a barrier formulation as defined in ~~any one of claims 1 to 9~~claim 1 to the skin.

19

~~1917~~ (currently amended) A method for the treatment and/or prophylaxis of infection, the method comprising applying a barrier formulation of ~~any one of claims 1 to 9~~claim 1 to a human or animal.

20

~~2018~~ (currently amended) A method for the treatment and/or prevention of hospital acquired infections, the method comprising administering a barrier formulation as defined in ~~any of claims 1 to 9~~claim 1 to a health care worker.

21

~~2119~~ (currently amended) A method of manufacturing a formulation comprising an emulsion having at least an oil phase and an aqueous phase wherein the oil phase comprises a silicone compound which method comprises the steps of:

- (a) preparing an oil phase containing a silicone compound;
- (b) preparing an aqueous phase;
- (c) mixing the oil phase and the aqueous phase together;
- (d) neutralizing the mixture with a neutralizing agent.

22

~~2220~~ (currently amended) A method as defined in ~~claim 21~~claim 19 wherein the water phase is added to the oil phase to obtain an oil-in-water emulsion.